Also known as Invanz
Ertapenem is a carbapenem antibiotic marketed by Merck as Invanz. It is structurally very similar to meropenem in that it possess a 1-β-methyl group.Source: Wikipedia
Estimated Total Cost: $450.49 for an average of 7 days supply
Patients are most commonly prescribed ertapenem to treat pyogenic skin infection, blastomycosis, rabies, and west nile virus.